Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors reduce progression of
chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range …

Drug repurposing in glomerular disease can deliver opportunities for steroid-free regimens,
enable personalized multi-target options for resistant or relapsing disease and enhance …

Chronic kidney disease (CKD) affects approximately 13% of people globally, including 20%–
48% with type 2 diabetes (T2D), resulting in significant morbidity, mortality, and healthcare …

Chronic kidney disease (CKD) is a major global health problem, affecting about 9.5% of the
population and 850 million people worldwide. In primary care, most CKD is caused by …

IgA nephropathy (IgAN) is considered the most common primary glomerulonephritis
worldwide with a predilection for Asian-Pacific populations and relative rarity in those of …

Immunoglobulin A nephropathy (IgAN) is a chronic, immune-mediated kidney disease
characterized by the deposition of galactose-deficient immunoglobulin A1 (Gd-IgA1) in the …

IgA nephropathy is a common glomerulonephritis consequent to the autoimmune response
to aberrant glycosylated immunoglobulin (Ig) A antibodies. Although it has historically been …

Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recommended
treatment for adults with chronic kidney disease (CKD), but uncertainty exists regarding their …

Cardiovascular disease (CVD) and kidney disease are the main causes of morbidity and
mortality in type 2 diabetes mellitus (T2DM). Globally, the incidence of T2DM continues to …

Aim Sodium-glucose cotransporter protein 2 (SGLT2) inhibitors have been shown to have
renoprotective effects in clinical studies. For further validation in terms of genetic variation …